XML 59 R53.htm IDEA: XBRL DOCUMENT
v2.4.0.8

Acquisitions - Narrative (Details) (USD $) | 3 Months Ended | 12 Months Ended | 0 Months Ended | 12 Months Ended | 0 Months Ended | 12 Months Ended | 0 Months Ended | 1 Months Ended | 12 Months Ended | 0 Months Ended | 1 Months Ended | 12 Months Ended | 0 Months Ended | 12 Months Ended | 0 Months Ended |  |  | 12 Months Ended | 0 Months Ended | 3 Months Ended | 1 Months Ended |  |  | 12 Months Ended | 0 Months Ended |  |  |  |  |  |  | 12 Months Ended | 3 Months Ended |  |  | 12 Months Ended | 0 Months Ended | 1 Months Ended |  |  | 0 Months Ended | 1 Months Ended | 12 Months Ended |  |  |  | 12 Months Ended | 0 Months Ended |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Dec. 31, 2013 | Sep. 30, 2013 | Jun. 30, 2013 | Mar. 31, 2013 | Dec. 31, 2012 | Sep. 30, 2012 | Jun. 30, 2012 | Mar. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | Dec. 19, 2012 Thomas Medical Products, Inc | Dec. 31, 2013 Thomas Medical Products, Inc | Dec. 31, 2012 Thomas Medical Products, Inc | Nov. 19, 2012 MediGroup | Dec. 31, 2013 MediGroup | Dec. 31, 2012 MediGroup | Jan. 31, 2012 Ostial Solutions, LLC | Aug. 31, 2012 Ostial Solutions, LLC | Jan. 31, 2012 Ostial Solutions, LLC | Dec. 31, 2013 Ostial Solutions, LLC | Dec. 31, 2012 Ostial Solutions, LLC | Sep. 02, 2011 Ash | Sep. 30, 2011 Ash | Dec. 31, 2013 Ash | Dec. 31, 2012 Ash | Oct. 04, 2013 Datascope | Dec. 31, 2013 Datascope | Dec. 31, 2013 Radial Assist | Apr. 06, 2011 Developed technology | Dec. 31, 2013 Developed technology | Dec. 31, 2012 Developed technology | Dec. 31, 2013 Developed technology Thomas Medical Products, Inc | Dec. 31, 2013 Developed technology MediGroup | Dec. 31, 2013 Developed technology Ostial Solutions, LLC | Dec. 31, 2013 Developed technology Ash | Sep. 10, 2010 Developed technology BioSphere | Dec. 31, 2010 Developed technology Datascope | Dec. 31, 2010 Developed technology Radial Assist | Aug. 31, 2011 Developed Technology Rights, Acquired in August 2011, Two | Dec. 31, 2013 Non-compete agreements | Dec. 31, 2012 Non-compete agreements | Dec. 31, 2013 Non-compete agreements Thomas Medical Products, Inc | Dec. 31, 2013 Non-compete agreements MediGroup | Dec. 31, 2013 Non-compete agreements Ostial Solutions, LLC | Dec. 20, 2013 License agreements and trademarks | Sep. 10, 2013 License agreements and trademarks | Dec. 31, 2013 License agreements and trademarks | Dec. 31, 2012 License agreements and trademarks | Sep. 10, 2010 License agreements and trademarks | Dec. 31, 2013 Customer Lists | Dec. 31, 2012 Customer Lists | Jan. 05, 2012 Customer Lists | Dec. 31, 2013 Customer Lists Thomas Medical Products, Inc | Dec. 31, 2013 Customer Lists MediGroup | Dec. 31, 2013 Customer Lists Ostial Solutions, LLC | Dec. 31, 2013 Customer Lists Ash | Dec. 31, 2010 Customer Lists Datascope | Dec. 31, 2010 Customer Lists Radial Assist | Dec. 31, 2013 Trademarks | Dec. 31, 2012 Trademarks | Dec. 31, 2013 Trademarks Thomas Medical Products, Inc | Dec. 31, 2013 Trademarks MediGroup | Dec. 31, 2013 Trademarks Ostial Solutions, LLC | Dec. 31, 2013 Trademarks Datascope | Dec. 31, 2013 Trademarks Radial Assist | Aug. 27, 2012 License Agreement Terms | Aug. 21, 2012 Distribution agreements | Jan. 05, 2012 Distribution agreements | May 31, 2012 Distribution agreements | Jan. 31, 2012 Distribution agreements | Dec. 31, 2013 Distribution agreements | Dec. 31, 2012 Distribution agreements | Aug. 07, 2012 Blockade Medical LLC | May 31, 2012 Intellectual Property Rights | Dec. 31, 2011 Intellectual Property Rights | Jul. 31, 2011 Intellectual Property Rights | Jun. 30, 2011 Intellectual Property Rights | Dec. 31, 2012 Intellectual Property Rights | Dec. 15, 2011 Intellectual Property Rights | Jul. 18, 2011 Intellectual Property Rights | Jun. 20, 2011 Intellectual Property Rights | Dec. 31, 2012 Development of Biomaterial Technology | Dec. 31, 2012 Covered Biliary In-Process Research and Development | Dec. 19, 2012 Wells Fargo Credit Agreement | Sep. 10, 2010 Wells Fargo Credit Agreement | Aug. 07, 2012 Special Membership Units Blockade Medical LLC
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues | $ 120,016,000 | $ 115,210,000 | $ 109,875,000 | $ 103,948,000 | $ 102,231,000 | $ 95,907,000 | $ 100,532,000 | $ 95,618,000 | $ 449,049,000 | $ 394,288,000 | $ 359,449,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payments to acquire businesses |  |  |  |  |  |  |  |  |  |  |  | 167,000,000 |  |  | 4,000,000 |  |  |  | 6,500,000 | 10,000,000 |  |  |  | 5,000,000 |  |  | 27,500,000 |  | 2,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Income before tax |  |  |  |  |  |  |  |  |  |  |  |  |  | 51,000 |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,600,000 | 191,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Useful life |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 10 years |  |  | 8 years | 8 years | 15 years | 15 years |  | 10 years | 10 years |  |  |  | 3 years | 7 years | 5 years | 4 years | 10 years |  |  |  |  |  |  | 12 years | 8 years | 8 years | 2 years | 6 years | 6 years |  |  | 15 years | 15 years | 15 years | 15 years | 15 years | 3 years | 10 years | 12 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average useful life |  |  |  |  |  |  |  |  |  |  |  |  | 8 years 6 months 18 days |  |  | 8 years 1 month 24 days |  |  |  |  | 14 years 7 months 6 days |  |  |  | 9 years |  |  | 10 years | 10 years 0 months 27 days |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Long-term debt issuance costs |  |  |  |  |  |  |  |  | 798,000 | 3,706,000 | 0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,700,000 | 798,000 |
Payments to acquire intangible assets |  |  |  |  |  |  |  |  | 1,617,000 | 1,460,000 | 2,077,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 500,000 |  |  | 500,000 |  |  |  |  |  | 350,000 | 250,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 750,000 | 250,000 |  | 1,000,000 | 1,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Accrued Liabilities, Current | 27,702,000 |  |  |  | 27,269,000 |  |  |  | 27,702,000 | 27,269,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 350,000 |  |  |  | 250,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets, Gross |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,029,000 | 1,035,000 |  |  |  | 700,000 | 250,000 | 3,783,000 | 2,733,000 |  | 20,626,000 | 20,468,000 |  |  |  |  |  |  |  | 7,622,000 | 7,311,000 |  |  |  |  |  |  |  |  |  |  | 5,176,000 | 5,176,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Accrued Liability, Current, Due Date in Relation to First Commercial Sale |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 30 days |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Liabilities incurred |  |  |  |  |  |  |  |  |  |  |  |  |  | 445,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net sales |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,900,000 |  |  | 169,000 |  |  |  |  | 457,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Goodwill, Period Increase (Decrease) |  |  |  |  |  |  |  |  |  |  |  |  | 381,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired receivables |  |  |  |  |  |  |  |  |  |  |  | 6,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Estimated uncollectible trade receivables acquired |  |  |  |  |  |  |  |  |  |  |  | 34,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisition-related costs |  |  |  |  |  |  |  |  |  |  |  |  | 2,700,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration, payment, 2013 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 150,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration, payment, 2014 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 150,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration, payment, 2015 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 150,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration, potential payment, 2016 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 150,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration, potential payment, 2017 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 150,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration, potential payment, 2018 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 150,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration, potential payment, 2019 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 150,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration, potential payment, 2020 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 150,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration, potential payment, 2021 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 150,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration, potential payment, 2022 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 150,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential payment, annual increase in net sales, minimum percent |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 8.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration, liability |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 403,000 |  |  | 4,300,000 |  | 4,300,000 |  |  | 1,300,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Intangible assets purchased |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 91,052,000 | 87,332,000 |  |  |  |  |  |  |  |  | 630,000 | 875,000 |  |  |  |  |  | 2,534,000 | 1,872,000 |  | 9,669,000 | 12,430,000 | 95,000 |  |  |  |  |  |  | 5,778,000 | 5,949,000 |  |  |  |  |  | 750,000 | 250,000 | 2,500,000 |  |  | 3,396,000 | 3,875,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration, potential payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 13,500,000 |  |  |  |  | 1,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 250,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cost method investments, special membership units |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 422,594
Cost method investments, ownership percentage |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 11.90% |  |  |  |  |  |  |  |  |  |  |  |  |
Payments to Acquire Investments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired in-process research and development |  |  |  |  |  |  |  |  | 0 | 2,450,000 | 5,838,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,000,000 | 2,000,000 | 1,000,000 | 1,000,000 | 4,900,000 |  |  |  | 500,000 | 400,000 |  |  |
Adjustment related to previous acquisitions |  |  |  |  |  |  |  |  | 381,000 | 280,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 280,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development, contingent consideration, liability |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,000,000 | 1,000,000 | 3,500,000 |  |  |  |  |
Research and development, contingent consideration, discounted liability |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 968,000 |  |  | $ 989,000 |  |  |  |  |  |  |  |

X
- Definition Accrued Liability, Current, Due Date in Relation to First Commercial Sale + References No definition available. + Details
Name: | mmsi_AccruedLiabilityCurrentDueDateinRelationtoFirstCommercialSale
Namespace Prefix: | mmsi_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Business Combination, Contingent Consideration, Payment, Next Twelve Months + References No definition available. + Details
Name: | mmsi_BusinessCombinationContingentConsiderationPaymentNextTwelveMonths
Namespace Prefix: | mmsi_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Business Combination, Contingent Consideration, Payment, Year Three + References No definition available. + Details
Name: | mmsi_BusinessCombinationContingentConsiderationPaymentYearThree
Namespace Prefix: | mmsi_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Business Combination, Contingent Consideration, Payment, Year Two + References No definition available. + Details
Name: | mmsi_BusinessCombinationContingentConsiderationPaymentYearTwo
Namespace Prefix: | mmsi_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Business Combination, Contingent Consideration, Potential Payment + References No definition available. + Details
Name: | mmsi_BusinessCombinationContingentConsiderationPotentialPayment
Namespace Prefix: | mmsi_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Business Combination, Contingent Consideration, Potential Payment, Annual Increase in Net Sales, Minimum Percent + References No definition available. + Details
Name: | mmsi_BusinessCombinationContingentConsiderationPotentialPaymentAnnualIncreaseInNetSalesMinimumPercent
Namespace Prefix: | mmsi_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Business Combination, Contingent Consideration, Potential Payment, Year Eight + References No definition available. + Details
Name: | mmsi_BusinessCombinationContingentConsiderationPotentialPaymentYearEight
Namespace Prefix: | mmsi_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Business Combination, Contingent Consideration, Potential Payment, Year Five + References No definition available. + Details
Name: | mmsi_BusinessCombinationContingentConsiderationPotentialPaymentYearFive
Namespace Prefix: | mmsi_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Business Combination, Contingent Consideration, Potential Payment, Year Four + References No definition available. + Details
Name: | mmsi_BusinessCombinationContingentConsiderationPotentialPaymentYearFour
Namespace Prefix: | mmsi_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Business Combination, Contingent Consideration, Potential Payment, Year Nine + References No definition available. + Details
Name: | mmsi_BusinessCombinationContingentConsiderationPotentialPaymentYearNine
Namespace Prefix: | mmsi_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Business Combination, Contingent Consideration, Potential Payment, Year Seven + References No definition available. + Details
Name: | mmsi_BusinessCombinationContingentConsiderationPotentialPaymentYearSeven
Namespace Prefix: | mmsi_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Business Combination, Contingent Consideration, Potential Payment, Year Six + References No definition available. + Details
Name: | mmsi_BusinessCombinationContingentConsiderationPotentialPaymentYearSix
Namespace Prefix: | mmsi_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Business Combination, Contingent Consideration, Potential Payment, Year Ten + References No definition available. + Details
Name: | mmsi_BusinessCombinationContingentConsiderationPotentialPaymentYearTen
Namespace Prefix: | mmsi_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Cost Method Investments, Interest Acquired, Number of Units + References No definition available. + Details
Name: | mmsi_CostMethodInvestmentsInterestAcquiredNumberOfUnits
Namespace Prefix: | mmsi_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Cost Method Investments, Ownership Percentage + References No definition available. + Details
Name: | mmsi_CostMethodInvestmentsOwnershipPercentage
Namespace Prefix: | mmsi_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Research and Development, Contingent Consideration, Discounted Liability + References No definition available. + Details
Name: | mmsi_ResearchAndDevelopmentContingentConsiderationDiscountedLiability
Namespace Prefix: | mmsi_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Research and Development, Contingent Consideration, Liability + References No definition available. + Details
Name: | mmsi_ResearchAndDevelopmentContingentConsiderationLiability
Namespace Prefix: | mmsi_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 20 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_AccruedLiabilitiesCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (a)(3) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275 + Details
Name: | us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_BusinessAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition For receivables acquired in a business combination, excluding certain loans and debt securities acquired in a transfer (as defined), this element represents the best estimate at the acquisition date of the contractual cash flows not expected to be collected, by major class of receivable, such as loans, direct finance leases (as defined), and any other class of receivables. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (b)(3) -URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4845-128472 + Details
Name: | us-gaap_BusinessCombinationAcquiredReceivablesEstimatedUncollectible
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition For receivables acquired in a business combination, excluding certain loans and debt securities acquired in a transfer (as defined), this element represents the gross contractual amounts receivable, by major class of receivable, such as loans, direct finance leases (as defined), and any other class of receivables. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (b)(2) -URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4845-128472 + Details
Name: | us-gaap_BusinessCombinationAcquiredReceivablesGrossContractualAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 25 -Paragraph 23 -URI http://asc.fasb.org/extlink&oid=21917927&loc=d3e1043-128460 + Details
Name: | us-gaap_BusinessCombinationAcquisitionRelatedCosts
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 30 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6578-128477 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 30 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6613-128477 + Details
Name: | us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of liability recognized arising from contingent consideration in a business combination. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 35 -Paragraph 1 -Subparagraph b -URI http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1392-128463 + Details
Name: | us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1392-128463 + Details
Name: | us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275 + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275 + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=14024403&loc=d3e13816-109267 + Details
Name: | us-gaap_GoodwillPeriodIncreaseDecrease
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (g) -URI http://asc.fasb.org/extlink&oid=14024403&loc=d3e13816-109267 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 25 -Paragraph 16 -URI http://asc.fasb.org/extlink&oid=21917927&loc=d3e961-128460 + Details
Name: | us-gaap_GoodwillPurchaseAccountingAdjustments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3291-108585 + Details
Name: | us-gaap_PaymentsOfDebtIssuanceCosts
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireBusinessesGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash outflow associated with the purchase of all investments (debt, security, other) during the period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275 + Details
Name: | us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(a)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 + Details
Name: | us-gaap_SalesRevenueGoodsNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration